Firstly, as the most frequently used glutaminase inhibitors such as BPTES and CB-839 are GLS1 selective, the resistance to glutaminase inhibition may be due to the differential expression of GLS1 and GLS2 in cells, as demonstrated in luminal and basal-like breast cancer cells (78). Here, GLS2 is linked to breast cancer.